In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus

Dalbavancin is a novel glycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It is characterized by a potent activity against numerous Gram-positive pathogens, a long elimination half-life and a favorable safety profile. Most recently, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacob, Benjamin, Makarewicz, Oliwia, Hartung, Anita, Brodt, Steffen, Roehner, Eric, Matziolis, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648795/
https://www.ncbi.nlm.nih.gov/pubmed/34873186
http://dx.doi.org/10.1038/s41598-021-02709-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648795/
https://www.ncbi.nlm.nih.gov/pubmed/34873186
http://dx.doi.org/10.1038/s41598-021-02709-x

Ejemplares similares